Title

Presentation

Operator: Good morning, and welcome to the ImmuCell Corporation conference call to discuss unaudited first quarter 2026 financial results. [Operator Instructions] Please note this event today is being recorded. I would now like to turn the conference call over to Joe Diaz of Lytham Partners. Please proceed.

Joe Diaz: Thank you, Chris. Good morning, and welcome. As the operator indicated, my name is Joe Diaz with Lytham Partners. We are the Investor Relations consulting firm for ImmuCell. I thank you for joining us today to discuss the unaudited earnings for the first quarter ended March 31, 2026. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements, which include any statement that refers to future events or expected future results or predictions about the steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today.

Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes or events is available under the cautionary note regarding forward-looking statements or better known as the safe harbor statement provided with the press release that the company filed last night, along with the company’s other periodic filings with the SEC. Information discussed on today’s call speaks only as of today, Friday, May 15, 2026. The company undertakes no obligation to update any information discussed on today’s call. Please note that references to certain non-GAAP financial measures may be made during today’s call. With that said, let me turn the call over to Oliver Te Boekhorst, President and CEO of ImmuCell Corporation, for opening remarks.

Oliver?

P. F. Te Boekhorst: Thanks, Joe, and good morning, everyone. It’s my pleasure to welcome you to today’s discussion of ImmuCell’s results for the first quarter of 2026. Starting this quarter, our discussion of results will be accompanied by a few key slides that are part of our new investor presentation. You can find that on our investor page, immucell.com/investors. In 2025, the company made significant changes to better position itself for success, including a strategic focus on the calf scours market and investments in leadership and in manufacturing yield improvement. In the first quarter of 2026, we are starting to see the results of this focus. We achieved our first ever $10 million revenue quarter, which is an exciting milestone for our commercial team and our manufacturing team.

And we also achieved 45% gross margins after absorbing legacy Re-Tain related costs that shifted from product development to gross — to cost of goods sold and reduced gross margins by approximately 2.4% during the quarter. We also grew net income 34% compared to the first quarter of 2025. In previous calls, we explained the rationale behind our new strategy to focus on First Defense, our leading calf scours preventative product. Since 1991, ImmuCell has competed successfully in the large growing market for calf scours prevention with a highly differentiated product portfolio that we believe has considerable runway for further expansion domestically and internationally. As we will discuss later in the call, we believe we are gaining share in this market, competing against the world’s largest animal health companies.

Historically, ImmuCell’s challenges have centered less around market demand and more on manufacturing capacity and product availability. And for a company our size, it made a lot of sense to focus on our successful on-market product and solve those challenges, and we are well underway to do that. Our results in the first quarter give us confidence in this decision. I will review some of these drivers in more detail and share some of our market observations after Timothy Fiori, our Chief Financial Officer, completes a deeper review of the financials for the first quarter of 2026. I now turn the call over to him. Tim?

Timothy Fiori: Thank you, Oliver. I’ll start with a short recap of product sales results, which are unchanged from our April 8 press release. All the numbers I’ll speak to are approximate and rounded. Product sales for the first quarter of 2026 came in at $10.4 million, an increase of 28.4% compared to what had been a record-breaking first quarter of 2025. Domestic sales for the first quarter grew 35.7% compared to the first quarter of 2025 to $9.7 million, while international sales for the first quarter declined 30.2% to about $600,000 in the same period. In terms of product specifics, we continue to be pleased with strong relative sales of Tri-Shield, our flagship product, which grew 38.5% in the first quarter of 2026 compared to the first quarter of 2025.

We realized gross margin improvement in the first quarter compared to prior year. Gross margin as a percentage of product sales increased to 45% during the first quarter of 2026 compared to 41.6% during the first quarter of 2025. We achieved this improvement despite a headwind of 2.4% in the first quarter of 2026 coming from costs associated with former Re-Tain assets, which year-over-year have shifted the cost of goods sold from product development expense. Year-over-year gross margin expansion in the first quarter of 2026 is coming from both price and manufacturing performance, partially offset by the aforementioned shift of former Re-Tain-related costs. Operating expenses increased to $2.7 million in the first quarter of 2026 compared to $2.2 million during the first quarter of 2025.

This was driven by increases in G&A, mostly related to investments in leadership and higher sales expense related to expanded commercial activities resuming a more normal pace following the backorder management period in the first quarter of 2025. Operating expenses were partially offset by lower product development expenses due to the previously mentioned shift of former Re-Tain-related expenses to cost of goods sold. Other expense decreased to $15,000 in the first quarter of 2026 compared to $330,000 of other income in the first quarter of 2025. This was driven by a nonrecurring insurance payment in the first quarter of 2025. To wrap up our income statement discussion, our net income was $1.9 million or $0.21 per share during the first quarter of 2026 compared to $1.4 million or $0.16 per share during the first quarter of 2025.

As Oliver mentioned, this is a 34% increase in net income year-over-year. As usual, we provided EBITDA figures in yesterday’s earnings release. We believe looking at EBITDA assists management and investors by looking at our performance across reporting periods on a consistent basis, excluding certain charges from our reported income before income taxes. EBITDA improved to $2.6 million in the first quarter of 2026 from $2.3 million in the first quarter of 2025. To wrap up with financials, let me highlight a few key balance sheet items. Our balance sheet as of March 31, 2026, is in a strong position with improvements versus year-end 2025, driven by the robust performance in product sales that we discussed previously. We ended the first quarter of 2026 with $6.8 million of cash on hand and $8.7 million of inventory.

Working capital increased from $13 million at the end of 2025 to $15 million at the end of the first quarter of 2026. We will continue to closely monitor and manage cash and our other assets as we balance long-term investment with near-term operational needs. With that, I will turn the call back to Oliver. Oliver?

P. F. Te Boekhorst: Thanks, Tim. Congratulations to the team for the excellent results in the first quarter of ’26. As I mentioned in my initial remarks, ImmuCell made the decision to focus on our scours preventative products called First Defense in late 2025. In the first quarter of this year, we achieved a record $10 million product sales and Tri-Shield particularly has showed very strong growth. It is the most advanced protection against scours that we offer in the market. Our focus on First Defense makes a lot of sense when you consider calf values have increased almost sevenfold in the past 3 years, and scours is a condition that affects up to 15% of pre-weaning calves and is the leading cause of death in these calves. We believe it causes up to $1 billion of economic burden in the U.S. due to treatment costs, performance losses and mortality.

High and rapidly increasing calf values have driven an increased appetite to invest in premium prevention products and scours is top of mind for many producers due to prevalence, morbidity and mortality. In 2025, we estimate U.S. farmers spent approximately $93 million on scours prevention products for about 14% year-over-year growth. In Q1 2026, we saw a slightly moderated 11% year-to-year growth for the overall scours biologics category, but ImmuCell’s first defense accelerated and accounted for what we estimated was nearly 80% of total category dollar expansion in the quarter. This is based on revenues to end customers as reported by distribution partners and market research firms. We are excited to report that our share of U.S. category spend expanded from 29.1% to 35.2%, and our share of animals treated increased from 15% to 18.1% between 2021 and the first quarter of 2026.

We believe this performance is driven by an increase in sales activity that started last quarter and the market’s increasing confidence in our product availability. Another driver is our premium pricing and positioning in the market. Premium pricing explains why our share of spend is higher than our share of animals treated. When I visited with our customers this quarter, they told me that First Defense products have several advantages that create a premium value proposition for them. Specifically, First Defense provides immediate protection for immune incompetent newborn calves against the 3 common pathogens that cause scours. And in addition, it also offers a lot of other bioactives that help calves stay healthy as a result of being derived from colostrum.

So our sales activities are now pivoting to winning new customers since about 55% of calves are still not getting any biological treatments at all. We believe the addressable market in the U.S. is more than $200 million. And internationally, the TAM is at least 5x as large. We will focus on these opportunities. As I discussed in previous calls, a key part of our strategy, given the tailwind from the macro environment and our excellent value proposition for customers is to ensure we have product available. This has been challenging for ImmuCell, and we are working hard every day to ensure we maximize yield and increase our output to keep up with demand. We made decisions in late 2025 to address manufacturing capacity constraints. And as you can see, we had an excellent first quarter of 2026, reaching a record of more than 450,000 manufacturing units of output per month.

And this compares to 380,000 manufacturing units per month we achieved in 2025, 344,000 in 2024 and 252,000 in 2023. This expansion of output helped improve our gross margin in addition to the price realization that Tim mentioned. Yield improvement is challenging and comes from doing a lot of different things really well every single day. There’s no magic bullet or a single big lever. The team got together and committed to ensuring availability. And then we improved our planning, which allowed for more preventative maintenance and balanced workflows. We reduced waste and scrap events, and we increased utilization by deploying some overtime and making incremental investments in various equipment to increase throughput. I can’t thank the team enough for their efforts.

Just a note about manufacturing units, they do not match up with revenue because of the different and changing price points of our products and the different number of units used for different products in our portfolio. There’s still a lot of work to do to stay ahead of demand for the remainder of 2026. We have to stay focused on managing and mitigating contamination risk. We have to keep providing great service to our colostrum supplying farms, and we have to manage yield improvement while we execute a major capacity expansion in our colostrum processing plant. We are pleased to announce that we reached a $2 million settlement with a former contract manufacturer, and we plan to deploy this cash to expand capacity to meet long-term demand. We plan to use more advanced process flows, state-of-the-art drying equipment and assets previously purchased to manufacture Re-Tain, the subclinical mastitis product that we have been developing until we focused on First Defense in December 2025.

We are finalizing these expansion plans, and we’ll communicate more information on future earnings calls. In previous calls, we discussed other investments we’re making to align with our new growth strategy. We hired an international business development executive with decades of dairy industry experience, and he is helping us transition from a reactive approach to international opportunities to a planful strategic approach. We are using a rigorous process involving management and the Board to understand market opportunities and product requirements, go-to-market investments, regulatory activity and time lines and our capacity expansion time lines as well. While we believe the international opportunity is significant, success will require disciplined market prioritization and time to prepare for and execute successfully.

And our efforts are focused on building the right foundation for sustainable global expansion. In the meantime, we have expanded our sales territories in the U.S. by 3 instead of the previously announced 2 territories since we see so much momentum in the domestic market. Finally, I will repeat what I’ve communicated on each call. Our top priority at ImmuCell is solid execution across the organization from sales to farm management to vaccine manufacturing and colostrum processing, including all the support functions that make future profitable growth possible. In the first quarter of the year, we announced changes to our corporate governance that supports this focus. We now have a smaller independent Board with 3 new board members who bring extensive animal health and functional expertise.

I look forward to working with the new Board on executing our focused strategy to deliver the day while we secure the future. With that said, we will be happy to take your questions. Let’s have the operator open up the lines.

Receive real-time insider trading and news alerts

Operator: [Operator Instructions] And today’s first question comes from Frank Gasca, a private investor.

Unknown Attendee: Outstanding quarter. And congratulations to the team on that performance. Could you talk a little bit about your First Defense in bulk product and its seasonality, its target market, whether or not it competes with existing products.

P. F. Te Boekhorst: Thank you for that question. Let me see if I can give you a little bit more detail. So our functional feed product is a non-USDA-approved product that uses a different manufacturing process that we use a different process to make it, but it essentially has our First Defense technology inside. It uses the same colostrum. And it reduces our cost to manufacture, and it’s offered to the market at a lower price point. And it is particularly useful for those operations that don’t want to feed each calf individually, but can add this to the water or colostrum or milk that they’re providing to the calves as a group. And so it has a different dynamic in that regard. We launched it late last year, second half of last year, essentially the new formulations of this product. And so we’re — it’s still in a product launch phase for us.

Operator: And the next question comes from George Melas with MKH Management.

George Melas: Totally outstanding quarter. Congratulations to a fantastic start. I want to ask a few questions about production capacity. I think you said that there’s no magic bullet to improving production and yield that there’s so many different levers. Can you tell us a little bit more about what were some of the key improvement that led to the yield improvement. And also with your current capacity and your 4 freezers, what do you see is your maximum capacity at this point?

P. F. Te Boekhorst: Thank you, George, for your question. There are some primary levers that we used in the last quarter, and there are some others that we are planning for that will hopefully yield more in the future. So the primary levers in the past 4 to 6 months have been improving our planning. So aligning our sales forecast with our production forecast on a very kind of SKU level and then planning our workflows so that it’s balanced so that one part of the team isn’t waiting for another part of the team. And with this planning, we also added some overtime capacity to some critical steps in the manufacturing process. And if you do that in a planned way, it’s actually manageable and it ties into back to the timing point that I made.

We also reduced waste in our process. There are parts of our process where we’re not using everything that we could. And so reusing and just focusing on that waste and reducing that increases output. Finally, there were a couple of steps in the process were minor, I would say, investments in capital and a bigger tank, some extra membranes, I mean some things like that really helped increase the throughput of a particular step in the process that was either a bottleneck or about to become a bottleneck. And so those are the key things that we’ve done. There’s other ways to further improve yields, and we’re looking at them on a continuous basis. We have a program in place that we’re all focused on to get to a higher yield. And we review that program more — several times a week, actually, we’re working on it.

And so we don’t know and have a specific number in mind of what is our maximum. We’re just improving yields kind of on a percentage basis, if you will, on a continuous basis. And at the same time, as I mentioned in my comments, it is time to think about a major capacity expansion. And so we’re very fortunate that we have the payment from our contract manufacturer that we can deploy towards that. And we are in the midst of actively planning a capacity expansion for our plan.

George Melas: Okay. Great. If I look at Slide #5, where you have basically the product mix over the last 3 years. Help us understand the trajectory of Tri-Shield, how it dipped during 2025 and has had a huge rebound. What drove that? Was that demand driven? I imagine you have some ability to influence demand, but it’s a puzzling — it seems to peak in the first quarter, but it’s — maybe help us understand that, if you can.

Timothy Fiori: Yes, George, it’s good to hear from you. This is Tim here. I think that the thing that’s challenging about some of the trends in the past few years even is the back order dynamic. So it’s really a lot of time dependent on what was available to sell to customers. And I think that creates some different dynamics that may not be intuitive. So that could be what you’re seeing. I mean, overall, the trend is that more customers seem to be shifting to Tri-Shield. That seems to be really where we’re growing. It’s our flagship product, and that’s the trend that we’re focused on.

P. F. Te Boekhorst: George, the only other thing that I would add to that is that Tri-Shield is a premium-priced product also compared to Dual-Force and our other products. And in the calving season that we just had, it’s the least price-sensitive segment that had a lot of demand in the last quarter or 2. And so that helps explain some of the uptake on Tri-Shield as well.

Operator: [Operator Instructions] And the next question is a follow-up from Frank Gasca, a private investor.

Unknown Attendee: Your increase in sales force again that you just mentioned. I’m curious as to what the main drivers of that is. And as far as regionality and the target market for those regions, could you get into that? Because it’s my understanding that the market is divided into dairy and beef. Where is your growth headed? Where is your sales directed?

P. F. Te Boekhorst: Thank you, Frank. We have expanded our sales team to essentially cover the entire country where there are calves, whether they’re beef or dairy because both industries use our product. Although traditionally more focused on the dairy segment where we’re seeing significant increases in the beef as well because beef calves are also increasing in value. And so with the increase in value of calf, investing in a preventative like First Defense makes a lot of sense for producers where they’re going to get a really good return on investment. So our goal is that we understand, and I understand this from my personal visits to customers, but the sales team sees this, of course, every day is that the more contact you have with customers to explain how our product works, the differences between our product and some of our competitors, which are vaccines and the differentiation that our product provides, it really helps close the deal, helps educate the customer, and they appreciate the time and investment in them.

So our strategy around sales force expansion is that more customer contact equals more revenue. And we’ve been seeing that now for a couple of quarters. And so we decided that it made sense to add a third territory, a territory in the west of the U.S. that had been, frankly, open for almost a year now. We decided to accelerate the hiring for that region. So I hope that gives you some color. We’re really looking at in each region of the country, what are the number of calves that are out there, what percentage of them are getting any treatment at all. And what does the sales cycle look like? We have some experience in that because in some regions, if you can close a deal faster than in others. And so we’re looking at kind of the fastest, highest return of our investment when we talk about adding commercial people to our team.

Operator: And at this time, this concludes our question-and-answer session. I would now like to turn the conference back over to Joe Diaz with Lytham Partners for any closing remarks.

Joe Diaz: Thank you, Chris, and I thank all of you for participating on today’s call. We look forward to talking with you again to review the results for the quarter ended June 30, 2026, during the week of August 10, 2026. Thanks again, and have a great day.

Operator: And the conference has now concluded. Thank you for attending today’s presentation, and you may now disconnect.

Receive real-time insider trading and news alerts